Review of our business Shire delivers record full-year revenue andstrong double digit growth in NonGAAP diluted earnings per ADS in2015.
Jeff Poulton Chief Financial Officer Through deep understanding of patients Revenues are derived primarily from two Overview needs, the Company is able to: sources sales of the Companys own The Company has grown both organically products and royalties: Serve patients with high unmet needs in and through acquisition, completing a select, commercially attractive specialty 95% 2014: 97% of total revenues are series of major transactions that have TAs: derived from product sales: and brought therapeutic, geographic and pipeline growth and diversification.
The Drive optimum performance of its 5% of total revenues are derived from Company will continue to conduct its own marketed products to serve patients royalties 2014: 3%.
research and development, focused on today: The markets in which the Company rare diseases, as well as evaluate companies, Build its pipeline of innovative specialist conducts its business are intensely products and pipeline opportunities that treatments through both R&D and competitive and highly regulated.
offer a strategic fit and have the potential Corporate Development activities todeliver value to all of the Companys The health-care industry is also experiencing: toenable the Company to serve patients stakeholders: patients, physicians, policy in the future.
Pressure from governments and makers, payers, investors and employees.
healthcare providers to keep prices low Shires in-licensing and acquisition efforts The Companys purpose is to enable while increasing access to drugs: are focused on products in specialist people with life altering conditions to lead markets with strong intellectual property Increased discount liability due to the better lives.
The Company will execute protection or other forms of market population of baby boomers covered onits purpose through its strategy and exclusivity and global rights.
Shire believes under Medicare, specifically those business model.
For further details of that a carefully selected and balanced beneficiaries receiving drug cost offset Shires strategy and business model, refer portfolio of products with strategically through the Medicare Part D Coverage to pages 12 to 15. aligned and relatively small-scale sales Gap the Donut Hole : forces will deliver strong results.
Increasing challenges from third party Company revenues, expenditures and payers for products to have demonstrable clinical benefit, with pricing netassets are attributable to the R&D, manufacture, sale and distribution of and reimbursement approval becoming increasingly linked to a products clinical pharmaceutical products within one reportable segment.
The Company also effectiveness and impact on overall costs of patient care: earns royalties where Shire has outlicensed products to third parties which Increased R&D costs, because are recorded as royalty revenues.
development programs are typically larger and take longer to get approval from regulators: 48 Shire Annual Report 2015 Strategic Report Governance Financial Statements Other Information Challenges to existing patents from dexamethasone, a therapy in late-stage Evidence of the successful progression of generic manufacturers: development for the treatment of infectious the late stage pipeline can be seen in the conjunctivitis, an ocular surface condition granting of approval and associated launches Governments and healthcare systems commonly referred to as pink eye.
This of the Companys products over the last favoring earlier entry of low cost generic acquisition further strengthens Shires five years.
In this time several products drugs: and late-stage pipeline, has a clear strategic have received regulatory approval including: Higher marketing costs, due to increased fitwith lifitegrast, which is in late-stage in the US, FIRAZYR in 2011, VYVANSE competition for market share.
development for treatment of dry eye forBED and NATPARA in 2015: in the EU, disease, and further demonstrates Shires ELVANSE TYVENSE for adults, INTUNIV Shires strategy has been developed to commitment to building a leadership for children and adolescents in2015.
address these industry-wide competitive position in ophthalmics.
This strategy has resulted in a Shires management reviews direct costs series of initiatives in the following areas: The acquisition of Dyax and their lead for all R&D projects by development phase.
pipeline product, DX-2930, alongside Markets Shires R&D costs in 2015 and 2014 Dyaxs currently marketed product included expenditure on programs in all KALBITOR, expands and extends Shires Shires current portfolio of approved stages of development.
The following table industry-leading HAE portfolio FIRAZYR products focuses on the following markets: provides an analysis of the Companys and CINRYZE, advancing its leadership HAE LSD, Neuroscience, and GI and direct R&D spend categorized by position in rare diseases and enhancing Internal Medicine.
Shire has also established development stage, based upon the theCompanys growth profile.
an Ophthalmics commercial unit in development stage of each program as preparedness for the commercialization The proposed combination with Baxalta atDecember 31, 2015 and 2014: ofShires ophthalmic pipeline candidates.
will enable Shire to become a global leader In addition, Shire has a number of marketed 2015 2014 in rare diseases.
products for other TAs from which it Year to December31, $M $M generates product revenues or royalties In 2015 Shire derived 27% 2014: 30% Early stage programs 177 170 from third parties.
In 2015 Shire derived ofproduct sales from outside of the US.
Late stage programs 225 253 approximately 45% of product sales Shirehas ongoing commercialization and Currently marketed fromrare disease products, 36% from late-stage development activities, which products 179 143 Neuroscience products and 19% from are expected to further supplement the GIand Internal Medicine products.
Shires diversification of revenues in the future, Total 581 566 early stage research is primarily focused including the following: onrare diseases.
In addition to the above, the Company Launch of INTUNIV in the EU for children recorded R&D employee costs of Shire has grown in part through acquisition and adolescents and the submission of $303million in 2015 2014: $270million which has brought therapeutic, geographic INTUNIV NDA in Japan: and other indirect R&D costs of $680 and pipeline growth and diversification.
Continued launch of REVESTIVE million 2014: $232million, comprising In2015 Shire acquired NPS Pharma, acrossEurope: depreciation and impairment charges.
On January 11, Review of MAA for NATPAR in the EU.
2016, Shire announced that the Boards of For a discussion of the Companys current Directors of Shire and Baxalta had reached development projects see pages 20 to 21.
R&D an agreement under which Shire will combine with Baxalta.
On January 22, In 2013 Shire combined the R&D 2016, Shire announced the closing of the organizations of its former divisions into acquisition of Dyax.
asingle One Shire R&D organization, focused around a prioritized portfolio of The acquisition of NPS Pharma added clinical development and research programs.
global rights to an innovative product Shire has focused its R&D efforts on five portfolio with multiple growth catalysts, TAs: Neuroscience, GI Metabolic Diseases, including GATTEX REVESTIVE and Renal Fibrotic Diseases, Ophthalmic NATPARA.
The acquisition of Meritage Diseases, and Diseases of the Complement provided global rights to OBS, a Phase Cascade.
Shire concentrates its resources 3-ready asset for the treatment of on obtaining regulatory approval for adolescents and adults with EoE, a rare, later-stage pipeline products within these chronic inflammatory GI disease.
This therapeutic areas and focuses its early enhances Shires late-stage pipeline and stage research activities in rare diseases.
builds upon the Companys rare disease and GI commercial infrastructure and expertise.
With the acquisition of Foresight Shire acquired the global rights to FST-100 topical ophthalmic drops combining 0.6% povidone iodine PVP-I and 0.1% Shire Annual Report 2015 49 Review of our business continued Patents and market exclusivity The loss or In 2014, Shire acquired: Corporate development expiration of patent protection or regulatory ViroPharma which added a leading Shire focuses its corporate development exclusivity with respect to any of the marketed product for the prophylactic activity on the acquisition and in-licensing Companys major products could have a treatment of HAE, CINRYZE, as well as of businesses, products or compounds material adverse effect on the Companys anumber of other marketed products which offer a strategic fit and have the revenues, financial condition and results and a pipeline of product candidates potential to deliver demonstrable value ofoperations, as generic or biosimilar inthe rare disease area: toall of the Companys stakeholders.
products may enter the market.
Companies Lumena which added global rights to selling generic products often do not need Recent mergers or acquisitions two late stage pipeline assets: SHP625, to complete extensive clinical studies On January 22, 2016 Shire completed the in Phase 2 clinical development with whenthey seek registration of a generic acquisition of Dyax which has expanded potential orphan indications: and SHP626, orbiosimilar product and accordingly, and extended Shires industry-leading in Phase 1b clinical development: aregenerally able to sell a generic version HAEportfolio by adding the currently of the Companys products at a much Fibrotech which added global rights to approved product, KALBITOR, SHP643 lower price.
SHP627 in Phase 1b, a new class of oral formerly DX-2930, a Phase 3 program drug with a novel mechanism of action forthe treatment of HAE as well as other As expected, in 2009 Teva and Impax which has the potential to address both programs in early stages of development.
commenced commercial shipments of their the inflammatory and fibrotic components authorized generic versions of ADDERALL On January 11, 2016 Shire announced of disease processes.
In addition Shire XR, which led to lower sales of branded thatthe Boards of Directors of Shire and has acquired rights to Fibrotechs library ADDERALL XR compared to the periods Baxalta had reached an agreement under of novel molecules including SHP628, prior to the authorized generic launches.
which Shire will combine with Baxalta, which is in pre-clinical development: and creating the global leader in rare diseases.
In 2011 generic versions of the Companys BIKAM which added global rights to Under the agreement Baxalta shareholders CARBATROL and REMINYL products SHP630 in pre-clinical development, are to receive $18.00 in cash and 0.1482 respectively were launched, which led forthe potential treatment of autosomal Shire ADS per Baxalta share.
Closing of tolower sales of these branded products dominant retinitis pigmentosa adRP.
thetransaction is subject to approval by compared to the period before loss Baxalta and Shire shareholders, certain Collaboration and licensing activity ofexclusivity.
regulatory approvals, redelivery of tax Shire has also entered into a number of In 2014 and 2015 generic versions of opinions delivered at signing and other collaboration and license agreements in theCompanys INTUNIV product was customary closing conditions.
For further recent years, including: launched, which led to lower sales of details, see Risks Related to the Proposed A worldwide licensing and collaboration Shires INTUNIV product compared to Merger with Baxalta Incorporated agreement with ArmaGen in 2014 to theperiod before loss of exclusivity.
includedwithin Principal Risks and develop and commercialize AGT-182, Uncertainties and The January 2016 Shire is engaged in various legal aninvestigational ERT for the potential Facilities Agreement in the Liquidity and proceedings with generic manufacturers treatment of both the central nervous Capital Resources section.
with respect to its VYVANSE and LIALDA system and somatic manifestations in patents.
For more detail of current patent In 2015, Shire acquired: patients with Hunter syndrome: litigation, see Note 18, Commitments A collaboration and license agreement NPS Pharma which added global rights andContingencies, Legal and other withSangamo to develop ZFP to an innovative product portfolio with proceedings to the consolidated financial Therapeutic clinical leads for Huntingtons multiple growth catalysts, including statements set forth in this Annual Report.
disease and a ZFP Therapeutic for GATTEX REVESTIVE with growing sales oneadditional gene target: and for the treatment of adults with SBS, arare GI condition: and NATPARA, the An agreement with Shionogi in 2012 only bioengineered hormone replacement toco-develop and co-commercialize therapy for use in the treatment of HPT, VYVANSE and INTUNIV in Japan.
arare endocrine disease: Meritage which provided Shire with worldwide rights to Meritages Phase 3-ready compound OBS for the potential treatment of adolescents and adults withEoE, a rare, chronic inflammatory GIdisease: and Foresight which added global rights to SHP640 formerly FST-100, a Phase-3 ready therapy for the treatment of infectious conjunctivitis, an ocular surface condition commonly referred to as pink eye.
50 Shire Annual Report 2015 Strategic Report Governance Financial Statements Other Information Organization and structure On October 22, 2013 Shire discontinued Total revenues were up 7% to In 2013 the Company integrated its operations the construction of its new manufacturing $6,417million 2014: $6,022million, due into a simplified One Shire organization in facility in San Diego.
Subsequently on to our product sales growth and higher order to drive future growth and innovation.
January 16, 2014, the Company sold and royalties and other revenues up 65%, Shire now comprises a single operating transferred certain of the assets relating primarily $115million of SENSIPAR and reportable segment.
For further details tothe manufacturing, marketing, sale royalties acquired with NPS Pharma.
see Note 24 Segmental reporting to the anddistribution of DERMAGRAFT to Operating income in 2015 was down 16% consolidated financial statements set forth Organogenesis Inc. For further information, to $1,420million 2014: $1,698million, as in this Annual Report.
As part of the see Note 9, Results of discontinued higher total revenues in 2015 were offset OneShire reorganization, the Company operations to the consolidated by higher operating costs as we advance undertook a review of all of its pipeline financialstatements.
our pipeline, invest behind current and programs and identified those projects anticipated product launches and include Results of operations for thatfit with the Companys new strategic NPS Pharma operating costs for the first direction and have an acceptable likelihood the years to December 31, time.
Operating income in 2015 was of success.
Following that review and heldback by higher IPR&D impairment 2015 and 2014 overall streamlining of the R&D organization, charges $644million in 2015 relating several clinical and pre-clinical projects Financial highlights for the year to toSHP625 and SHP608, and higher were discontinued which resulted in the December 31, 2015 are as follows: intangible asset amortization charges elimination of a significant number of R&D following the acquisition of NPS Pharma, Product sales excluding INTUNIV were roles and functional roles that support which were in part offset by a net 1 up 10% up 14% on a Non GAAP CER R&Din Basingstoke, and some positions creditfrom changes in the fair value 2 basis, with growth driven by VYVANSE were re-located.
ofcontingent consideration liabilities up 19% to $1,722million, CINRYZE $150million.
In addition the Company also relocated its up23% to $618million, LIALDA international commercial hub from Nyon, Diluted earnings per ordinary share from MEZAVANT up 8% to $684million Switzerland to Zug, Switzerland.
continuing operations decreased 62% to andFIRAZYR up 22% to $445million.
$2.20 2014: $5.76 primarily as a result GATTEX REVESTIVE and NATPARA In 2014 certain aspects of the One Shire of comparison to strong diluted earnings acquired with NPS Pharma contributed program were temporarily put on hold per ordinary shares in 2014 which 3percentage points, or $166million of dueto AbbVies offer for Shire, which was benefited from the$1,635million break product sales growth.
Subsequent fee received following AbbVies tothe termination of AbbVies offer, Shire Product sales growth in 2015 was held terminated offer forShire.
announced on November 10, 2014 its plans back, as expected, by 4 percentage to relocate over 500 positions to Lexington, points due to the foreign exchange Massachusetts from its Chesterbrook, headwinds from the strong US dollar, Pennsylvania, site and establish Lexington primarily affecting sales of ELAPRASE, as the Companys US operational REPLAGAL and VPRIV.
headquarters in continuation of the One Total product sales were up 5% on 2014 Shire efficiency program.
This relocation 1 up 9% on a Non GAAP CER basis to streamlines business globally through two $6,100million 2014: $5,830million.
principal locations, Massachusetts and Totalproduct sales were held back Switzerland, with support from regional and bysignificantly lower INTUNIV sales country-based offices around the world.
down80% to $65million following the introduction of generic competition from For further details see Note 5 December 2014.
Reorganization costs to the consolidated financial statements set forth in this AnnualReport.
1 CER, a Non GAAP financial measure.
CER performance is determined by comparing 2015 performance restated using 2014 exchange rates to actual 2014 reported performance.
2 Lisdexamfetamine dimesylate LDX currently marketed as VYVANSE in the US and Canada, VENVANSE in Latin America and ELVANSE in certain territories in the EU for the treatment of Attention Deficit Hyperactivity Disorder ADHD ADHD and in the US for the treatment of moderate to severe BED.
Shire Annual Report 2015 51 Review of our business continued Total revenues The following table provides an analysis of the Companys total revenues by source: 2015 2014 Change Year to December31, $M $M $M Product sales 6,099.9 5,830.4 5% Royalties 300.5 160.8 87% Other revenues 16.3 30.9 -47% Total 6,416.7 6,022.1 7% Product sales Year to Year to Product Non GAAP US December 31, December 31, sales CER prescription Exit market 1 2 2 2015 2014 growth growth growth share Year to December31, $M $M % % % % Net product sales: VYVANSE 1,722.2 1,449.0 19 21 8 17 LIALDA MEZAVANT 684.4 633.8 8 10 10 36 3 3 CINRYZE 617.7 503.0 23 24 n a n a 3 3 ELAPRASE 552.6 592.8 -7 4 n a n a 3 3 FIRAZYR 445.0 364.2 22 25 n a n a 4 4 REPLAGAL 441.2 500.4 -12 1 n a n a ADDERALL XR 362.8 383.2 -5 -4 10 5 3 3 VPRIV 342.4 366.7 -7 1 n a n a PENTASA 305.8 289.7 6 6 -7 12 FOSRENOL 177.6 183.0 -3 4 -9 3 3 3 GATTEX REVESTIVE 141.7 n a n a n a n a 3 3 XAGRID 100.8 108.5 -7 7 n a n a INTUNIV 65.1 327.2 -80 -79 -70 1 3 3 NATPARA 24.4 n a n a n a n a Other product sales 116.2 128.9 -10 -1 n a n a Total product sales 6,099.9 5,830.4 5 9 1 On a Constant Exchange Rate CER basis, which is a Non GAAP measure, computed by comparing 2015 product sales and revenues restated using 2014 average foreign exchange rates to 2014 actual product sales and revenues.
For reconciliation to US GAAP please see page 159.
2 This information is an estimate derived from the use of information under license from the following IMS Health information service: IMS NPA Weekly for the period January 17, 2014 to January 22, 2016.
IMS expressly reserves all rights, including rights of copying, distribution and republication.
Exit market share represents the average US market share in the month ended December 31, 2015.
3 IMS NPA Data not available.
4 Not sold in the US in the year to December 31, 2015.
VYVANSE ADHD and BED LIALDA MEZAVANT UC CINRYZE prophylactic treatment VYVANSE product sales grew strongly The 8% growth in product sales for ofHAE up19% in 2015.
Growth was driven by LIALDA MEZAVANT in 2015 was primarily CINRYZE sales were up 23% on 2014, prescription growth in the US up 8%, the driven by higher prescription demand primarily driven by strong growth in 1 benefit of price increases and to a lesser up10% and, to a lesser extent, a price patients on therapy and, to a lesser extent, 1 1 extent the benefit of stocking in 2015 as increase taken at the beginning of 2015. sales also benefited from a price increase compared to destocking in 2014 and The growth was partially offset by higher taken since 2014. growth from international markets.
This sales deductions as a percentage of sales ELAPRASE Hunter syndrome growth was partially offset by higher sales in 2015 as compared to 2014 and, to a ELAPRASE product sales were down deductions as a percentage of product lesser extent the impact of destocking in 2 7% up 4% on a Non GAAP CER basis sales in 2015 as compared to 2014.
2015 compared to stocking in 2014. reflecting the negative impact of foreign Litigation proceedings regarding VYVANSE Litigation proceedings regarding LIALDA exchange movements and to a lesser are ongoing.
Further information about are ongoing.
Further information about extent a lower average price due to pricing thislitigation can be found in Note 18, thislitigation can be found in Note 18, pressures and geographic mix.
These Commitments and Contingencies, Legal Commitments and Contingencies, Legal negative factors were partially offset by and other proceedings to the consolidated and other proceedings to the consolidated higher volumes primarily due to an increase financial statements.
in the number of patients on therapy.
52 Shire Annual Report 2015 Strategic Report Governance Financial Statements Other Information FIRAZYR HAE Royalties $22.0million relating to the SHP613 IPR&D FIRAZYR product sales growth was up intangible asset, following the decision to Year to Year to 22% compared to 2014, driven by a higher discontinue further development based December December number of patients on therapy and, to a onportfolio prioritization as well as 31, 31, 1 lesser extent, the effect of a price increase unexpected challenges and complexities 2015 2014 Change in the US market.
Also $M $M % included in 2014 R&D expenditure is a REPLAGAL Fabry disease SENSIPAR 114.5 n a payment of $12.5 million in respect of REPLAGAL sales were down 12% 3TC and ZEFFIX 49.1 33.9 45% in-licensed and acquired products.
compared to 2014 up 1% on a Non GAAP FOSRENOL 46.1 51.4 -10% Excluding these costs, R&D expenditure in 2 CER basis, as the benefit of more patients the year to December 31, 2015 increased INTUNIV 27.8 22.0 26% on therapy was more than offset by the by 6% or by $56 million, due to the ADDERALL XR 26.0 28.9 -10% negative impact of foreign exchange and inclusion of NPS Pharma costs since Other 37.0 24.6 50% toa lesser extent, pricing pressures.
February 2015 and increased investment in Total 300.5 160.8 87% existing pipeline programs, partially offset ADDERALL XR ADHD by lower spend on certain programs in ADDERALL XR product sales were down Royalty income increased by 87% in 2015 2014 which was not repeated in 2015.
5% in 2015, as growth in prescription due primarily to the inclusion of royalty demand up 10% was more than offset by R&D expenditure in the year to December31, income receivable from Amgen Inc. for higher sales deductions as a percentage of 2015 included depreciation of $21.7million SENSIPAR following the acquisition of product sales in 2015 compared to 2014.
VPRIV Gaucher disease SG&A from continuing operations Cost of product sales from continuing VPRIV product sales were down 7% SG&A expenditure increased to 2 operations up1%on a Non GAAP CER basis, as $2,341.2million for the year to December 31, Cost of product sales decreased to sales growth was negatively impacted by 2015 from $2,025.8 million.
SG&A $969.0million for the year to December 31, foreign exchange and the impact of new expenditure as a proportion of product 2015 16% of product sales, down from competition in the US market partially sales also increased by three percentage $979.3 million in the corresponding period offset by higher utilization per patient.
points to 38% of product sales for the year in 2014 17% of product sales.
Cost of to December 31, 2015 compared with PENTASA UC product sales as a percentage of product 35%of product sales in the corresponding PENTASA product sales were up 6% as sales was one percentage point lower 1 period in 2014, due to the inclusion of NPS thebenefit of price increases was partially compared to the same period in 2014, as Pharmas SG&A costs, higher amortization offset by higher sales deductions as a the impact of the inclusion of lower margin of intangible assets acquired with NPS percentage of product sales and lower products acquired with NPS Pharma was Pharma and increased sales and marketing prescription demand in 2015 compared more than offset by lower charges on the spend supporting the launch of VYVANSE to2014.
unwind of fair value adjustments on for the treatment of BED and the anticipated acquired inventories.
GATTEX SBS launch of lifitegrast for the treatment of DED.
Shire acquired GATTEX REVESTIVE For the year to December 31, 2015 cost For the year to December 31, 2015 SG&A throughits acquisition of NPS Pharma ofproduct sales included depreciation of included depreciation of $70.7million onFebruary21, 2015, and recorded $46.1million 2014: $57.1million.
2014: $81.9million and amortization of salesof$142million in2015 up 51% 3 R&D from continuing operations $498.7million 2014: $243.8million.
R&D expenditure increased to $1,564.0million Gain on sale of product rights INTUNIV ADHD for the year to December 31, 2015 26% of For the year to December 31, 2015 Shire INTUNIV product sales were down 80% product sales, compared to $1,067.5million recorded a net gain on sale of product compared to 2014, reflecting the impact of in the corresponding period in 2014 18% rights of $14.7million 2014: $88.2million generic competitors since December 2014. ofproduct sales.
R&D expenditure in 2015 due primarily to the re-measurement of the includes impairment charges of $467million NATPARA Hypocalcemia in contingent consideration receivable relating relating to the SHP625 IPR&D intangible Hypoparathyroidism to the divestment of DAYTRANA.
In 2014 asset, due to a lower probability of regulatory Shire made NATPARA available on April 1, Shire additionally recorded a net gain approval following trial results and revised 2015, after acquiring the product through onsale of product rights following the commercial potential, and $176.7 million its acquisition of NPS, and following a divestment of CALCICHEW, VANCOCIN, relating to the SHP608 IPR&D intangible strong US launch, sales of $24million ESTRACE and EXPUTEX.
asset, following preclinical toxicity findings.
R&D expenditure in 2014 includes impairment charges of $190.3 million, primarily relating to the SHP602 IPR&D intangible asset of$166.0million, following the Phase 2 trialbeing placed on clinical hold and 1 The actual net effect of price increases on current period net sales compared to the comparative period is difficult to quantify due to the various managed care rebates, Medicaid discounts, other discount programs in which the Company participates and fee for service agreements with wholesalers customers.
2 CER, a Non GAAP financial measure.
3 Sales prior to February 21, 2015 were recorded by NPS Pharma, prior to the acquisition by Shire.
Shire Annual Report 2015 53 Review of our business continued Reorganization costs The effective rate of tax on income from Accounts receivable, net For the year to December 31, 2015 continuing operations in 2014 includes the Accounts receivable, net increased by Shirerecorded reorganization costs of receipt of the break fee from AbbVie and $166.1million to $1,201.2million at $97.9million 2014: $180.9million primarily recognition of a net credit to income taxes December 31, 2015 December 31, 2014: related to the relocation of roles from of $235million, following the settlement of $1,035.1million, primarily due to the Chesterbrook to Lexington.
2014 also certain tax positions with the Canadian inclusion of NPS Pharmas accounts included costs relating to the One Shire revenue authorities in 2014.
The Company receivable and an increase in revenue.
reorganization, which included termination has obtained advice that the break fee Days sales outstanding slightly decreased benefits and other reorganization costs.
should not be taxable in Ireland.
Company has therefore concluded that Integration and acquisition costs Inventories notax liability should arise and did not For the year to December 31, 2015 Shire Inventories increased by $90.6million recognize a tax charge in the income recorded net integration and acquisition to$635.4million at December 31, 2015 statement in 2014.
The relevant tax return costs of $39.8million, representing December 31, 2014: $544.8million, was submitted on September 23, 2015. acquisition and integration costs of primarily due to the inventories acquired $189.7million, primarily related to NPS Discontinued operations aspart of the acquisition of NPS Pharma Pharma, ViroPharma, Baxalta and Dyax.
The loss from discontinued operations and an increase in inventories of certain These costs were offset by a net credit of forthe year to December 31, 2015 was products following continued sales growth.
$149.9million on the change in fair value of $34.1million net of tax 2014: gain of Goodwill contingent consideration liabilities, primarily $122.7million primarily relating to a change Goodwill increased by $1,672.9million relating to SHP625 acquired with Lumena in estimate for onerous lease provisions.
to$4,147.8million at December 31, 2015 and SHP608 acquired with Lotus Tissue 2014 included a tax credit of $211.3million December 31, 2014: $2,474.9million, Repair, Inc.. primarily driven by a tax benefit arising principally due to the acquisitions of In 2014 Shire recorded integration and following a reorganization of the NPSPharma, Meritage and Foresight.
acquisition costs of $158.8million, Regenerative Medicine business Other intangible assets, net comprising acquisition and integration undertaken in Q4 2014, associated with Other intangible assets increased by costs of $144.1million, primarily related thedivestment of the DERMAGRAFT $4,238.9million to $9,173.3million at toViroPharma, and a $14.7million charge business in Q1 2014.
The gain was December 31, 2015 December 31, 2014: relating to the change in fair values of partiallyoffset by costs associated with the $4,934.4million, principally due to the contingent consideration.
divestment of the DERMAGRAFT business, intangible assets acquired with NPS including a loss on re-measurement of Interest expense Pharma, Meritage and Foresight, offset contingent consideration receivable from For the year to December 31, 2015 Shire byIPR&D intangible asset impairment Organogenesis to its fair value.
incurred interest expense of $41.6million charges and intangible asset amortization.
Interest expense in Financial condition at Short term borrowings 2015 principally relates to interest and Short term borrowings increased by December 31, 2015 financing costs incurred on facilities $661.5million to $1,511.5million at drawndown in respect of the acquisition and2014 December 31, 2015 December 31, 2014: ofNPSPharma.
Cash & cash equivalents $850.0million, reflecting the utilization of Taxation from continuing operations short term debt facilities to partially fund Cash and cash equivalents decreased The effective tax rate on income from by$2,846.9million to $135.5million at the acquisition of NPS Pharma and the continuing operations was 3% 2014: 2%.
recognition of secured non-recourse December 31, 2015 December 31, 2014: $2,982.4million, primarily due to the use debtliabilities assumed as part of the The effective rate of tax on income from NPSPharma acquisition.
ofexisting cash and cash equivalents to continuing operations in 2015 is low partially fund the acquisitions of NPS primarily due to the deferred tax accounting Other current liabilities Pharma, Foresight and Meritage.
for acquisitions in higher tax territories, Other current liabilities decreased by including the amortization and impairments $118.5million to $144.0million at In the year to December 31, 2014 Cash of acquired intangible assets and December 31, 2015 December 31, 2014: andcash equivalents included the receipt changesin the fair values of contingent $262.5million principally due to the of the $1,635 million break fee in relation consideration liabilities, which do not reduce reduction in the fair value of contingent toAbbVies terminated offer for Shire, the Companys cash tax liability.
In addition, consideration payable associated with thebenefit of the $417 million repayment the effective rate of tax on income from theSHP625 IPR&D intangible asset.
received from the Canadian revenue continuing operations is reduced by authorities and the net proceeds of Non-current deferred tax liabilities increased R&D credits, the effect of the $554.5million from Shires line of credit Non-current deferred tax liabilities increased finalization of various tax returns and and other borrowings.
These inflows were by $995.3million to $2,205.9million at changes in profit mix including the benefit offset by the cost of acquiring ViroPharma, December 31, 2015 December 31, 2014: in higher tax territories of significant Lumena and Fibrotech.
$1,210.6million primarily due to deferred reorganization and integration costs.
tax liabilities arising on intangible assets partially offset by deferred tax assets arising on tax attributes both acquired withNPSPharma, Meritage and Foresight.
54 Shire Annual Report 2015 Strategic Report Governance Financial Statements Other Information Other non-current liabilities Shire has a revolving credit facility of Interest on any loans made under the RCF Other non-current liabilities increased by $2,100million which matures in 2020, is payable on the last day of each interest $62.1million to $798.8million at $750million of which was utilized as period, which may be one week or one, December31, 2015 December 31, 2014: December 31, 2015. two, three or six months at the election $736.7million principally due to a change ofShire, or as otherwise agreed with the In connection with the acquisitions of in estimate in respect of onerous lease lenders.
The interest rate for the RCF is: NPSPharma and Dyax and the proposed liabilities and recognition of contingent LIBOR or, in relation to any revolving loan combination with Baxalta, Shire entered consideration payable in respect of the in euro, EURIBOR : plus 0.30% per year into a number of facility arrangements in Meritage acquisition, offset by a reduction subject to change depending upon i the the year to December 31, 2015 and in the fair value of contingent consideration prevailing ratio of Net Debt to EBITDA each subsequently in 2016.
The details of these payable associated with the SHP608 and as defined in the RCF in respect of the facility arrangements are presented below.
most recently completed financial year or Shire also assumed non-recourse secured financial half year and ii the occurrence debt obligations as part of the NPS Pharma Liquidity and capital and continuation of an event of default in acquisition with a carrying value of respect of the financial covenants or the resources $81.4million as at December 31, 2015.
See failure to provide a compliance certificate.
Note 16, Borrowings to the consolidated General financial statements.
Shire shall also pay i a commitment fee The Companys funding requirements equal to 35% of the applicable margin on depend on a number of factors, including In addition Shire has access to certain available commitments under the RCF for the timing and extent of its development short-term uncommitted lines of credit the availability period applicable thereto programs: corporate, business and which it utilizes from time to time to provide and ii a utilization fee equal to a 0.10% product acquisitions: the level of resources short-term flexibility in cash management.
per year of the aggregate of all outstanding required for the expansion of certain At December 31, 2015, these lines of credit loans up to an aggregate base currency manufacturing and marketing capabilities were not utilized.
amount equal to $700million, b 0.15% per as the product base expands: increases in year of the amount by which the aggregate Revolving Credit Facilities Agreement accounts receivable and inventory which base currency amount of all outstanding On December 12, 2014, Shire entered into may arise with any increase in product loans exceeds $700million but is equal to a $2,100million revolving credit facilities sales: competitive and technological or less than $1,400million and c 0.30% agreement the RCF with a number of developments: the timing and cost of per year of the amount by which the financial institutions, for which Abbey obtaining required regulatory approvals aggregate base currency amount of all National Treasury Services PLC trading fornew products: the timing and quantum outstanding loans exceeds $1,400million.
asSantander Global Banking and Markets, of milestone payments on business Bank of America Merrill Lynch International combinations, in-licenses and collaborative The RCF includes customary Limited, Barclays Bank PLC, Citigroup projects: the timing and quantum of tax representations and warranties, covenants Global Markets Limited, Lloyds Bank PLC, and dividend payments: the timing and and events of default, including requirements The Royal Bank of Scotland PLC and quantum of purchases by the Employee that Shires i ratio of Net Debt to EBITDA Sumitomo Mitsui Banking Corporation Benefit Trust of Shire shares in the market in respect of the most recently ended acted as mandated lead arrangers and to satisfy awards granted under Shires 12-month relevant period each as defined bookrunners and DNB Bank ASA, The employee share plans: and the amount in the RCF must not, at any time, exceed Bank of Tokyo-Mitsubishi UFJ, Ltd. Credit ofcash generated from sales of Shires 3.5:1 except that, following an acquisition Suisse AG, London Branch, Deutsche products and royalty receipts.
fulfilling certain criteria, Shire may on a Bank Luxembourg S. A. Goldman Sachs once only basis elect to increase this ratio An important part of Shires business Bank USA, Mizuho Bank, Ltd. and Morgan to a 5.5:1 for the relevant period in which strategy is to protect its products and Stanley Bank International Limited acted the acquisition was completed b 5.0:1 in technologies through the use of patents, asarrangers.
Shire is an original borrower respect of the first relevant period following proprietary technologies and trademarks, and original guarantor under the RCF.
the relevant period in which the acquisition to the extent available.
The Company Shirehas agreed to act as guarantor for any was completed and c 4.5:1 in respect of intends to defend its intellectual property of its subsidiaries that become additional the second relevant period following the and as a result may need cash for funding borrowers under the RCF.
As at December relevant period in which the acquisition the cost of litigation.
31, 2015 the Company utilized $750million wascompleted, and ii ratio of EBITDA to of the RCF.
The Company finances its activities through Net Interest for the most recently ended cash generated from operating activities: 12-month relevant period each as defined The RCF, which terminates on December credit facilities: private and public offerings in the RCF must not be less than 4.0:1.
12, 2020, may be applied towards financing of equity and debt securities: and the the general corporate purposes of Shire.
The RCF restricts subject to certain proceeds of asset or investment disposals.
The RCF incorporates a $250million US exceptions, Shires ability to incur additional dollar and euro swingline facility operating Shires balance sheet includes financial indebtedness, grant security over as a sub-limit thereof.
$135.5million of cash and cash equivalents its assets or provide loans grant credit.
Further, any lender may require mandatory prepayment of its participation if there isachange of control of Shire, subject tocertain exceptions for schemes of arrangement and analogous schemes.
Shire Annual Report 2015 55 Review of our business continued Events of default under the RCF include, Interest on any loans made under the The January 2016 Facilities Agreement subject to customary grace periods and January 2016 Facilities Agreement will be restricts, subject to certain exceptions, materiality thresholds: i non-payment payable on the last day of each interest Shires ability to incur additional financial ofany amounts due under the finance period, which may be one week or one, indebtedness, grant security over its assets documents as defined in the RCF, two, three or six months, or as otherwise or provide loans grant credit.
Further, any ii failure to satisfy any financial covenants, agreed with the lenders.
The interest rate lender may require mandatory prepayment iii material misrepresentation in any of the applicable to the January 2016 Facilities of its participation if there is a change finance documents, iv failure to pay, or Agreement is LIBOR plus 1.25 percent per ofcontrol of Shire, subject to certain certain other defaults, under other financial annum, increasing by: i 0.25 percent per exceptions for schemes of arrangement indebtedness, v certain insolvency annum on July 11, 2016 and on each and analogous schemes.
In addition, in eventsor proceedings, vi material adverse subsequent date falling at three month certain circumstances and subject to changes in the business, operations, intervals thereafter until and excluding certain broad exceptions, the net cash assets or financial condition of Shire as a April 11, 2017 and ii 0.50 percent per proceeds of disposals and certain issues, whole, vii if it becomes unlawful for Shire annum on April 11, 2017 and on each loans, sales or offerings of debt securities or any successor parent company or subsequent date falling at three month by any member of Shires group must anyof their respective subsidiaries that intervals thereafter.
beapplied in cancellation of the available areparties to the RCF to perform their commitments under the January 2016 Shire shall also pay a commitment fee on obligations thereunder or viii if Shire Facilities Agreement and, if applicable, the available but unutilized commitments orany successor parent company or any mandatory prepayment of any loans made under the January 2016 Facilities Agreement subsidiary thereof which is a party to the under the January 2016 Facilities Agreement.
for the availability period applicable to each RCF repudiates such agreement or other facility.
With effect from first utilization, Events of default under the January 2016 finance document, among others.
thecommitment fee rate will be 35 percent Facilities Agreement include, subject to The RCF is governed by the English law.
Before first customary grace periods and materiality utilization, the commitment fee rate shall thresholds: i non-payment of any Term Loan Facilities Agreement beincreased in stages from 10 percent to amountsdue under the finance documents January 2016 Facilities Agreement 35percent of the applicable margin over as defined in the January 2016 Facilities On January 11, 2016, Shire as original the period to May 11, 2016.
Agreement, ii failure to satisfy any financial guarantor and original borrower, entered covenants, iii material misrepresentation into, an $18.0 billion bridge facilities The January 2016 Facilities Agreement inany of the finance documents, iv failure agreement with, among others, Barclays includes customary representations and to pay, or certain other defaults, under Bank PLC Barclays and Morgan Stanley warranties, covenants and events of other financial indebtedness, v certain Bank International Limited, acting as default, including requirements that Shires insolvency events or proceedings, mandated lead arrangers and bookrunners i ratio of Net Debt to EBITDA in respect of vi material adverse changes in the the January 2016 Facilities Agreement.
the most recently ended 12-month relevant business, operations, assets or financial The January 2016 Facilities Agreement period, each as defined in the January 2016 condition of Shire as a whole, vii if it comprises two credit facilities: i a Facilities Agreement, must not, at any time, becomes unlawful for Shire or any $13.0billion term loan facility which, exceed 3.5:1, except that following the successor parent company or any of their subject to a one year extension option combination with Baxalta, or any other respective subsidiaries that are parties to exercisable at Shires option, matures on acquisition fulfilling certain criteria, Shire the January 2016 Facilities Agreement to January 11, 2017 January 2016 Facility A may elect on a once only basis to increase perform their obligations thereunder or and ii a $5.0billion revolving loan facility this ratio to a 5.5:1 for the relevant period viii if Shire or any successor parent which, subject to a one year extension in which the acquisition was completed, company or any subsidiary thereof which option exercisable at Shires option, matures b 5.0:1 in respect of the first relevant is a party to the January 2016 Facilities on January 11, 2017 January 2016 Facility period following the relevant period in Agreement repudiates the January 2016 B. Shire has agreed to act asguarantor which the acquisition was completed and Facilities Agreement or any other finance for any of its subsidiaries that become c 4.5:1 in respect of the second relevant document, among others.
additional borrowers under the January 2016 period following the relevant period in Facilities Agreement.
As of February 23, 2016 which the acquisition was completed, and The January 2016 Facilities Agreement is the January 2016 Facility was undrawn.
ii ratio of EBITDA to Net Interest, for the governed by English law.
most recently ended 12-month relevant January 2016 Facility A may be used to period each as defined in the January finance the cash consideration payable in 2016 Facilities Agreement, must not be respect of the proposed combination with less than 4.0:1.
Baxalta and certain costs related to the proposed combination.
January 2016 Facility B may be used to finance the redemption of all or part of Baxaltas seniornotes upon completion of the proposed combination.
56 Shire Annual Report 2015 Strategic Report Governance Financial Statements Other Information November 2015 Facilities Agreement time, exceed 3.5:1, except that following an January 2015 Facility Agreement On November 2, 2015, Shire as original acquisitions fulfilling certain criteria, Shire On January 11, 2015, Shire entered into an guarantor and original borrower entered may elect on a once only basis to increase $850million term facility agreement with, into a $5.6 billion facilities agreement with, this ratio to a 5.5:1 for the relevant period among others, Citigroup Global Markets among others, Morgan Stanley Bank in which the acquisition was completed, Limited acting as mandated lead arranger International Limited and Deutsche Bank b 5.0:1 in respect of the first relevant and bookrunner the January 2015 Facility AG, London Branch acting as mandated period following the relevant period in Agreement with an original maturity date lead arrangers and bookrunners the which the acquisition was completed and of January 10, 2016.
The maturity date was November 2015 Facilities Agreement.
c 4.5:1 in respect of the second relevant subsequently extended to July 11, 2016 in The November 2015 Facilities Agreement period following the relevant period in line with the provisions within the January comprises three credit facilities: i a $1.0billion which the acquisition was completed, 2015 Facility Agreement allowing the maturity term loan facility which, subject to aone and ii the ratio of EBITDA to Net Interest date to be extended twice, at Shires option, year extension option exercisable atShires inrespect of the most recently ended by six months on each occasion.
option, matures on November 2, 2016 12-month relevant period each as defined The January 2015 Facility Agreement was November 2015 Facility A, ii a $2.2billion in the November 2015 Facilities Agreement available to finance the purchase price amortizing term loan facility which matures must not be less than 4.0:1. payable in respect of Shires acquisition on November 2, 2017 November 2015 The November 2015 Facilities Agreement ofNPS Pharma including certain related Facility B and iii a $2.4billion amortizing restricts, subject to certain exceptions, costs.
On September 28, 2015 the term loan facility which matures on Shires ability to incur additional financial Company reduced the January 2015 November 2, 2018 November 2015 indebtedness, grant security over its assets Facility Agreement by $100 million.
As Facility C. or provide loans grant credit.
Further, any atDecember 31, 2015 the January 2015 As of December 31, 2015, the November lender may require mandatory prepayment Facility Agreement, was fully utilized in the 2015 Facilities Agreement was undrawn.
of its participation if there is a change of amount of $750 million.
In January 2016 InJanuary 2016 the November 2015 control of Shire, subject to certain and at various points thereafter, the Facilities Agreement was utilized in full exceptions for schemes of arrangement Company canceled parts of the January tofinance the purchase price payable in and analogous schemes.
On February 22, respect of Shires acquisition of Dyax and 2016, the Company repaid in full the Events of default under the November 2015 certain costs related to the acquisition.
Facilities Agreement include, subject to Interest on any loans made under the customary grace periods and materiality 2013 Facilities Agreement November 2015 Facilities Agreement is thresholds: i non-payment of any On November 11, 2013, Shire entered into payable on the last day of each interest amountsdue under the finance documents a $2,600million facilities agreement with, period, which may be one week or one, as defined in the November 2015 among others, Morgan Stanley Bank two, three or six months, or as otherwise FacilitiesAgreement, ii failure to satisfy International Limited acting as mandated agreed with the lenders.
The interest rate any financial covenants, iii material lead arranger and bookrunner the 2013 applicable is LIBOR plus, in the case of misrepresentation in any of the finance Facilities Agreement.
The 2013 Facilities November 2015 Facility A, 0.55% per annum, documents, iv failure to pay, or certain Agreement comprised two credit facilities: in the case of November 2015 Facility B, other defaults, under other financial i a $1,750million term loan facility and 0.65% per annum and, in the case of indebtedness, v certain insolvency ii an $850million term loan facility.
November 2015 Facility C, 0.75% per eventsor proceedings, vi material adverse On December 13, 2013 and at various points annum, in each case until delivery of the changes in the business, operations, thereafter, the Company cancelled parts first compliance certificate required to be assets or financial condition of Shire as a ofthe 2013 Facilities Agreement.
On delivered after the date of the November whole, vii if it becomes unlawful for Shire September 28, 2015 the Company repaid 2015 Facilities Agreement and is subject or any successor parent company or any in full the remaining balance of $350million tochange thereafter depending on i the of their respective subsidiaries that are under the 2013 Facilities Agreement.
prevailing ratio of Net Debt to EBITDA parties to the November 2015 Facilities eachas defined in the November 2015 Agreement to perform their obligations Short-term uncommitted lines of credit Facilities Agreement in respect of the thereunder or viii if Shire or any successor Credit lines mostrecently completed financial year or parent company or any subsidiary thereof Shire has access to various Credit lines financial half year and ii the occurrence which is a party to the November 2015 from a number of banks which provide and continuation of an event of default in Facilities Agreement repudiates the flexibility to short-term cash management respect of the financial covenants or failure November 2015 Facilities Agreement or any procedures.
These Credit lines can be to provide a compliance certificate.
other finance document, among others.
withdrawn by the banks at any time.
The Credit lines are not relied upon for core The November 2015 Facilities Agreement The November 2015 Facilities Agreement is liquidity.
As at December 31, 2015 these includes customary representations governed by English law.
Credit lines were not utilized.
andwarranties, covenants and events of default, including requirements that Shires i ratio of Net Debt to EBITDA in respect of the most recently ended 12-month relevant period, each as defined in the November 2015 Facilities Agreement must not, at any Shire Annual Report 2015 57 Review of our business continued Financing Cash flow activity Net cash provided by financing activities Shire anticipates that its operating cash Net cash provided by operating activities was $439.0 million for the year to flow together with available cash, cash for the year to December 31, 2015 December 31, 2015, principally due to the equivalents and the RCF will be sufficient decreased by $1,891.4 million or 45% to drawings, net of subsequent repayments, tomeet its anticipated future operating $2,337.0 million 2014: $4,228.4 million.
made under Shires various borrowing expenses, capital expenditures, tax and Net cash provided by operating activities facilities to partially fund the NPS Pharma, interest payments, lease obligations, in2014 included the receipt of the Meritage and Foresight acquisitions.
In repayment of the term loans and milestone $1,635million break fee in relation to addition the Company made dividend payments as they become due over the AbbVies terminated offer for Shire, and payments of $134.4 million.
thebenefit of the $417 million repayment Net cash provided by financing activities received from the Canadian revenue Shires existing cash, January 2016 was $554.5million for the year to authorities.
Excluding these items net cash Facilities Agreement and the RCF are December 31, 2014, principally due to the provided by operating activities in 2015 sufficient to finance Shires proposed drawings, net of subsequent repayments, increased by $160.6 million as a result of combination with Baxalta.
made under the facilities to partially fund higher cash receipts from gross product the ViroPharma acquisition.
In addition sales and royalties, which were partially If the Company decides to acquire other theCompany paid cash of $551.4million offset by higher operating expense businesses, it expects to fund these tosettle the convertible debt assumed payments, including payments in relation acquisitions from cash resources, the withViroPharma, received cash of tointegration, reorganization activities and RCF, term loan facilities and through new $346.7million upon settlement of a employee retention payments following borrowings including issuances of debt purchased call option acquired with AbbVies terminated offer for Shire.
securities or the issuance of new equity ViroPharma and made dividend payments ifnecessary.
Net cash provided by operating activities of $121.2million.
for the year to December 31, 2014 Sources and uses of cash Outstanding letters of credit increased by $2,765.4million or 189% to The following table provides an analysis At December 31, 2015, the Company had $4,228.4million 2013: $1,463.0million ofthe Companys gross and net cash irrevocable standby letters of credit and primarily due to the receipt of the excluding restricted cash, as at guarantees with various banks totaling $1,635million break fee in relation to December31, 2015 and 2014: $48million, providing security for the AbbVies terminated offer for Shire, the Companys performance of various 2015 2014 benefit of the $417million repayment obligations.
These obligations are Year to December31, $M $M received from the Canadian revenue primarilyin respect of the recoverability Cash and cash authorities and higher cash receipts from ofinsurance claims, lease obligations and 1 equivalents 135.5 2,982.4 gross product sales, offset by payments for supply commitments.
Long term borrowings 69.9 sales deductions, payments of acquisition and integration costs in respect of the Short term borrowings 1,511.5 850.0 acquisitions of ViroPharma, Lumena and Other debt 13.4 13.7 Fibrotech, costs in connection with Abbvies Total debt 1,594.8 863.7 terminated offer for Shire and cash payments 2 Net debt cash 1,459.3 2,118.7 in respect of the One Shire reorganization.
1 Net cash used in investing activities was Substantially all of the Companys cash and cashequivalents are held by foreign subsidiaries $5,619.9 million in the year to December i. e, those subsidiaries incorporated outside of 31, 2015, principally relating to the cash Jersey, Channel Islands, the jurisdiction of paid for the acquisition of NPS Pharma of incorporation of Shire plc, Shires holding company.
$5,220 million excluding cash acquired The amount of cash and cash equivalents held with NPS Pharma of $42 million and for the byforeign subsidiaries has not had, and is not acquisitions of Foresight $299 million and expected to have, a material impact on the Companys liquidity and capital resources.
2 Net debt cash is a Non GAAP measure.
The Company believes that Net debt cash is a useful Net cash used in investing activities was measure as it indicates the level of net cash $4,030.6million in the year to December borrowings after taking account the cash and 31, 2014, principally relating to the cash cash equivalents that could be utilized to pay paid for the acquisition of ViroPharma of down the outstanding borrowings.
See above $3,997million excluding cash acquired forreconciliation to cash and cash equivalents.
with ViroPharma of $233million and for theacquisition of Lumena of $300million excluding cash acquired with Lumena of $46million, offset by the proceeds received on the sale of non-core product rights.
58 Shire Annual Report 2015 Strategic Report Governance Financial Statements Other Information Cash Requirements At December 31, 2015 the Companys cash requirements for short and long term liabilities reflected on the Balance Sheet and other contractual obligations were as follows: Payments due by period Less than 1-3 3-5 More than Total 1 year years years 5 years $M $M $M $M $M Long-term debt obligation 69.9 69.9 Short-term debt obligation 1,511.5 1,511.5 1 Operating leases obligation 372.3 51.5 75.4 59.6 185.8 2 Purchase obligations 1,406.4 934.3 304.1 167.3 0.7 3 Other long term liabilities reflected ontheBalance Sheet 624.8 416.9 191.5 16.4 Total 3,984.9 2,497.3 866.3 418.4 202.9 1 The Company leases certain land, facilities, motor vehicles and certain equipment under operating leases expiring through 2021.
2 Purchase obligations include agreements to purchase goods, investments or services including clinical trials, contract manufacturing and capital equipment, including open purchase orders, that are enforceable and legally binding and that specify all significant terms.
Shire expects to fund these commitments with cash flows from operating activities.
3 Unrecognized tax benefits and associated interest and penalties of $201.2million are included within payments due in one to three years.
In addition to the above contractual Off-balance sheet arrangements Inflation obligations, the Company is committed There are no off-balance sheet Although at reduced levels in recent tomake milestone payments principally arrangements, aside from those outlined years, inflation continues to apply upward arising from the in-licensing or acquisition above, that have, or are reasonably likely pressure on the cost of goods and services of products, assets and businesses, tohave, a current or future material effect which are used in the business.
However, contingent upon the occurrence of future on the Companys financial condition, the Company believes that the net effect of events and therefore payment is not revenues or expenses, results of inflation on its revenues and operations has yetdue.
At December 31, 2015, the operations, liquidity, capital expenditures been minimal during the past three years.
Company is contingently committed to orcapital resources.
Treasury policies and organization payup to approximately $0.8 billion Foreign currency fluctuations The Companys principal treasury aggregate contractual amount in respect A number of the Companys subsidiaries operations are coordinated by its corporate of potentialfuture research and development have a functional currency other than the treasury function.
All treasury operations milestonepayments and up to approximately US Dollar.
As such, the consolidated are conducted within a framework of $1.1billion aggregate contractual amount financial results are subject to fluctuations policies and procedures approved annually in respect of commercial milestones as in exchange rates, particularly in the Euro, by the Board of Directors.
As a matter of aresult of prior business combinations Swiss Franc and Pound Sterling against policy, the Company does not undertake andin-licensing agreements.
speculative transactions that would increase under these agreements are generally its credit, currency or interest rate exposure.
dueand payable only upon achievement The accumulated foreign currency ofcertain development, regulatory and translation differences at December 31, Interest rate risk commercial milestones.
2015 of $156.4million are reported within The Company is principally exposed to accumulated other comprehensive income interest rate risk on any borrowings under From a business perspective, these in the consolidated balance sheet and the Companys various debt facilities see payments signify that the product is foreign exchange losses for the year to Liquidity and Capital Resources for details successfully moving through development December 31, 2015 of $26.5million are of each of the Companys facilities.
Interest and is now generating or is more likely to reported in the consolidated statements on each of these facilities is set at floating generate cash flows from product sales.
rates, to the extent utilized.
Shires exposure However, it is not possible to predict with under these facilities is to US dollar interest reasonable certainty whether these At December 31, 2015, the Company rates.
At December 31, 2015 the Company milestones will be achieved or the timing hadoutstanding swap and forward had fully utilized the January 2015 Facility oftheir achievement.
As a result, these foreignexchange contracts to manage the Agreement and utilized $750million of the potential payments are not included in currency risk associated with intercompany RCF.
Other facilities were not utilized at thetable of contractual obligations.
At December 31, 2015 the fair December 31, 2015. value of these contracts was a net liability of $9.6million.
Shire Annual Report 2015 59 Review of our business continued The Company regularly evaluates the Transactional exposure arises where basis in the consolidated balance sheet.
interest rate risk on its facilities.
At transactions occur in currencies different Asat December 31, 2015 the potential December 31, 2015 the Company tothe functional currency of the relevant effect of rights of set-off associated with considered the risks associated with subsidiary.
The main trading currencies the foreign exchange contracts would be floating interest rates on borrowings under ofthe Company are the US dollar, Pounds an offset to both assets and liabilities of its facilities as appropriate.
A hypothetical Sterling, Swiss Franc, Canadian dollar $1.4 million, resulting in net derivative one percentage point increase or decrease andthe Euro.
It is the Companys policy assets and derivative liabilities of $0.5million in the interest rates applicable to drawings that these exposures are minimized to and $10.1 million, respectively.
Further under the January 2015 Facility Agreement theextent practicable by denominating details are included below.
and the RCF at December 31, 2015 would transactions in the subsidiarys Foreign exchange risk sensitivity increase interest expense by approximately functionalcurrency.
The following exchange rate sensitivity $15 million per annum or would decrease Where significant exposures remain, the analysis summarizes the sensitivity of the the interest expense by approximately Company uses foreign exchange contracts Companys reported revenues and net $7million per annum.
being spot, forward and swap contracts income to hypothetical changes in the The Company is also exposed to interest to manage the exposure for balance sheet average annual exchange rates of the Euro, rate risk on its restricted cash, cash and assets and liabilities that are denominated Pound Sterling and Swiss Franc against cash equivalents and on foreign exchange in currencies different to the functional theUS Dollar assuming a hypothetical contracts on which interest is set at floating currency of the relevant subsidiary.
These 10% strengthening of the US Dollar rates.
This exposure is primarily limited to assets and liabilities relate predominantly againsteach of the aforementioned US dollar, Pounds sterling and Euro interest tointer-company financing.
The foreign currencies in the year to December 31, rates.
As the Company maintains all of exchange contracts have not been 2015 see Table1 below.
itscash, liquid investments and foreign designated as hedging instruments.
A 10% weakening of the US Dollar against exchange contracts on a short term basis Cashflows from derivative instruments the aforementioned currencies would have for liquidity purposes, this risk is not arepresented within net cash provided an equal and opposite effect.
In the year to December byoperating activities in the consolidated 31, 2015 the average interest rate received cash flow statement, unless the derivative The table below provides information about on cash and liquid investments was less instruments are economically hedging the Companys swap and forward foreign than 1% per annum.
These cash and liquid specific investing or financing activities.
exchange contracts by currency pair.
The investments were primarily invested in table presents the net principal amounts Translational foreign exchange exposure USdollar term deposits with banks and and weighted average exchange rates of arises on the translation into US dollars of money market and liquidity funds.
All contracts the financial statements of non-US dollar have a maturity date of less than three No derivative instruments were entered functional subsidiaries.
intoduring the year to December 31, 2015 At December 31, 2015 the Company had tomanage interest rate exposure.
The Concentration of credit risk 39 swap and forward foreign exchange Company continues to review its interest Financial instruments that potentially contracts outstanding to manage currency rate risk and the policies in place to expose Shire to concentrations of credit risk.
The swap and forward contracts manage the risk and may enter into risk consist primarily of short-term cash mature within 90 days.
The Company derivative instruments to manage interest investments, derivative contracts and trade didnot have credit risk related contingent rate risk in the future.
accounts receivable from product sales features or collateral linked to the derivatives.
and from third parties from which the Foreign exchange risk The Company has master netting Company receives royalties.
Cash is The Company trades in numerous agreements with a number of counterparties invested in short-term money market countries and as a consequence has to these foreign exchange contracts and instruments, including money market and transactional and translational foreign onthe occurrence of specified events, liquidity funds and bank term deposits.
theCompany has the ability to terminate Themoney market and liquidity funds in contracts and settle them with a net which Shire invests are all triple A rated by payment by one party to the other.
The both Standard and Poors and by Moodys Company has elected to present derivative credit rating agencies.
assets and derivative liabilities on a gross Table 1 Table 2 Increase Increase Principal reduction reduction Value of Weighted in revenues in net income Amount Average Fair $M $M Receivable Exchange Value December 31, 2015 $M Rate $M Euro 71.0 45.0 Swap foreign exchange contracts Pound Sterling 17.0 9.0 Receive USD Pay EUR 270.4 1.08 1.1 Swiss Franc 3.1 2.0 Receive GBP Pay USD 258.1 1.52 8.3 Receive USD Pay JPY 21.4 0.01 0.3 Receive USD Pay SEK 14.4 0.12 0.3 Receive USD Pay MXN 11.6 0.06 0.3 Receive USD Pay AUD 7.4 0.72 0.1 60 Shire Annual Report 2015 Strategic Report Governance Financial Statements Other Information The Company is exposed to the credit risk countries outside of the US, specifically, To date the Company has not incurred of the counterparties with which it enters Argentina, Greece, Italy, Portugal and material losses on accounts receivable in into bank term deposit arrangements and Spain collectively the Relevant Countries the Relevant Countries, and continues to derivative instruments.
The Company limits the Company is experiencing delays in consider that such accounts receivable this exposure through a system of internal theremittance of receivables due from arerecoverable.
credit limits which vary according to ratings government-owned or governmentOther than the accounts receivable from assigned to the counterparties by the major supported healthcare providers.
The government-owned or supported healthcare rating agencies.
The internal credit limits are Company continued to receive remittances providers outlined above, the Company approved by the Board and exposure against in relation to government-owned or does not hold any other government debt these limits is monitored by the corporate government-supported healthcare providers from the Relevant Countries.
The counterparties to in the Relevant Countries in the year to the Company does not consider it is these derivatives contracts are major December 31, 2015, including receipts of currently exposed to significant credit international financial institutions.
$116.0million and $100.0million in respect riskoutside of the Relevant Countries.
of Spanish and Italian receivables, respectively.
The Companys revenues from product The Companys exposure to Greece, both The Company continues to evaluate all its sales in the US are mainly governed by in terms of gross accounts receivable and accounts receivable for potential collection agreements with major pharmaceutical annual revenues, is not material.
risks and has made provision for amounts wholesalers and relationships with other where collection is considered to be pharmaceutical distributors and retail The Companys aggregate accounts doubtful.
If the financial condition of the pharmacy chains.
For the year to receivable, net of the allowance for doubtful Relevant Countries or other countries December 31, 2015 there were three accounts, in total from government-owned suffersignificant deterioration, such that customers in the US that accounted for or government-supported healthcare their ability to make payments becomes 47% of the Companys product sales.
providers in those territories in which the uncertain, additional allowances for However, such customers typically have Company is experiencing the most significant doubtful accounts may be required, and significant cash resources and as such delays, i. e. in the Relevant Countries losses may be incurred, in future periods.
therisk from concentration of credit is areas follows see Table 3 below.
Any such loss could have an adverse effect considered acceptable.
The Company has Accounts receivable due from governmenton the Companys financial condition and taken positive steps to manage any credit owned or government-supported healthcare results of operations.
risk associated with these transactions and providers in the Relevant Countries of operates clearly defined credit evaluation Strategic Report $106million 2014: $77 million are split procedures.
However, an inability of one The Strategic Report comprises bycountry as follows: ormore of these wholesalers to honor pages1to61 of this Annual Report Greece $7 million 2014:$4 million : theirdebts to the Company could have an andAccounts.
Italy$49 million 2014:$30 million : adverse effect on the Companys financial Portugal$9 million 2014: $11 million : Approved by the Board and signed on its condition and results of operations.
Spain $33 million 2014:$15 million : and behalf by: A substantial portion of the Companys Argentina $8 million 2014: $17 million.
accounts receivable in countries outside The Company continues to receive ofthe United States is derived from remittances in relation to governmentproduct sales to government-owned owned or government-supported healthcare  healthcare providers in the Relevant Countries and in providers.
The Companys recovery of the year to December 31, 2015 received these accounts receivable is therefore $294million in settlement of accounts dependent upon the financial stability receivable in the Relevant Countries: andcreditworthiness of the relevant $3million was from Greece: $100million governments.
In recent years global Bill Mordan from Italy: $13million from Portugal: andnational economic conditions Company Secretary $116million from Spain: and $62million havenegatively affected the growth, February 23, 2016 from Argentina.
creditworthiness and general economic condition of certain markets in which the Company operates.
As a result, in some Table 3 December 31, December 31, 2015 2014 $M $M Total accounts receivable, net in the RelevantCountries 127 118 Total accounts receivable, net in the Relevant Countries as a percentage oftotal outstanding accounts receivable, net 11% 11% Accounts receivable, net due from government-owned or governmentsupported healthcare providers for the Relevant Countries 106 77 Shire Annual Report 2015 61
